Akums Drugs Q4 FY26 Results: Revenue Growth Expectations
- March 10, 2026
- Posted by: Neeraj Pandey
- Category: News
Akums Drugs and Pharmaceuticals Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Akums Drugs and Pharmaceuticals was listed on the National Stock Exchange (NSE) on 06-Aug-2024. Akums Drugs and Pharmaceuticals share has its face value of 2 per share, and its NSE symbol is AKUMS. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.
Akums Drugs and Pharmaceuticals Q4 Results 2026 Preview
- Akums Drugs and Pharmaceuticals Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 10-14% YoY increase compared to the same quarter last year.
- Profit After Tax, or PAT, is projected to rise 11-15% YoY.
- EBITDA to rise 12%.
- Akums Drugs and Pharmaceuticals is expected to show Moderate Growth Expected in its revenue.
Click and Sign Up to Get Live Updates on Q4 Results
Akums Drugs and Pharmaceuticals Share Performance
- Over the past six months, Akums Drugs and Pharmaceuticals share price has 20% by 10-14% to 485.9.
- Moreover, over the past year, the stock has 34% by Up
- Despite this weak short-term performance, Akums Drugs and Pharmaceuticals stock has delivered a financially sound 150% return over the past 5 years.
- As of today, 10-03-2026, the Akums Drugs and Pharmaceuticals share price is trading at 485.9 per share.
Key Factors to Watch for Akums Drugs and Pharmaceuticals Q4 Results FY26
- Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
- Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
- Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
- Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
- Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.
About Akums Drugs and Pharmaceuticals
Akums Drugs and Pharmaceuticals is a prominent contract manufacturer in India, producing pharmaceuticals, nutraceuticals, and Ayurvedic formulations. The company provides end-to-end solutions—formulation, manufacturing, and packaging—to domestic and international clients across diverse therapeutic categories.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Final Thoughts
Akums Drugs and Pharmaceuticals is gear up to announce its Q4 FY26 results. Analysts expect 10-14% revenue growth, a 11-15% rise in PAT, and a 12% rise in EBITDA. Akums Drugs and Pharmaceuticals focuses on revenue growth from order execution, margin improvement, a strong order book, and management.
Stay informed with Univest blogs to get real-time updates on Akums Drugs and Pharmaceuticals Q4 results FY26.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Adani Green Energy Q4 FY26 Results Preview: Renewable Energy Momentum
Adani Enterprises Q4 FY26 Earnings Preview: What to Expect
ACE Q4 FY26 Earnings Preview: Infra and Equipment Demand
Accelya Solutions Q4 FY26 Results Preview: Aviation Tech Demand
Abbott India Q4 FY26 Earnings Preview: Healthcare Growth Outlook
